Vanishing white matter disease is a genetic leukoencephalopathy caused by mutations in eukaryotic translation initiation factor 2B. Patients experience a slowly progressive neurological deterioration with episodes of rapid clinical worsening triggered by stress. The disease may occur at any age and leads to early death.
Introduction
Vanishing white matter disease (OMIM number 603896) may occur at any age, but is most often seen in children. It is one of the most prevalent inherited leukoencephalopathies in children (van der Knaap et al., 2006) . Clinically, it is characterized by chronic progressive cerebellar ataxia and spasticity with less prominent cognitive decline. Typically, there are episodes of rapid clinical worsening triggered by stress. The disease is invariably fatal (van der Knaap et al., 2006) . VWM is caused by mutations in any of the genes encoding the five subunits of the eukaryotic translation initiation factor 2B (eIF2B) (Leegwater et al., 2001; der Knaap et al., 2002) . eIF2B plays an essential role in the control of protein synthesis under normal and different stress conditions (Scheper et al., 2007) . Although eIF2B is ubiquitously expressed, VWM is mainly or exclusively a leukoencephalopathy.
Neuropathology of post-mortem VWM brain tissue shows diffuse lack of myelin and rarefaction to massive cystic degeneration of the cerebral white matter. The cerebellar white matter may also be affected, but without signs of tissue loss.
Around the cavitated areas the degree of reactive gliosis is disproportionately low compared with the degree of white matter damage. The astrocytes that are found are immature, dysmorphic and show an abnormal intermediate filament composition with absolute overexpression of the delta subunit of the glial fibrillary acidic protein (GFAP) (van der Knaap et al., 2006; Bugiani et al., 2010 Bugiani et al., , 2011 . The mechanisms contributing to such meagre astrocytic reaction and to the absent glial scarring are unknown. In the same brain regions, paucity of myelin is observed while total cell numbers are remarkably increased (van der Knaap et al., 2006; Bugiani et al., 2010) . A significant proportion of these cells are proliferating plateletderived growth factor receptor alpha-(PDGFRα) and neuron-glial antigen 2 (NG2)-positive pre-myelinating oligodendrocyte progenitor cells (Bugiani et al., 2011) . The number of oligodendrocyte progenitor cells is disproportionately high compared with that of mature myelinating oligodendrocytes, suggesting inhibited oligodendrocyte progenitor cell maturation as a possible explanation for the lack of myelin (Bugiani et al., 2011) . Microglia are inconspicuous, and inflammatory cells are absent (Bugiani et al., 2010) .
In the developing and adult brain, astrocyte-restricted precursor cells and reactive astrocytes express the transmembrane protein CD44, a receptor for the major extracellular matrix glycosaminoglycan hyaluronan (Liu et al., 2004; Sherman & Back, 2008) . In diverse disease conditions, including multiple sclerosis, hyaluronan accumulates in regions enriched in CD44 + astrocytes where oligodendrocyte progenitor cell numbers increase, but their maturation into myelin-forming cells is inhibited (Back et al., 2005) . Hyaluronan also plays a role in regulating astrogliosis and glial scar formation (Hou et al., 2005; Struve et al., 2005; Lin et al., 2009; Khaing et al., 2011) .
In this study, we investigate the hypothesis that the affected white matter in VWM is enriched in CD44 + astrocyte-restricted precursor cells and accumulates hyaluronan. Hyaluronan overabundance could be the common causal determinant of meagre glial scarring and inhibited oligodendrocyte progenitor cell maturation typically observed in VWM white matter.
Materials and methods

Patients
Brain tissue from seven patients with genetically proven VWM was collected at autopsy at the VU University Medical Centre in Amsterdam, The Netherlands, or obtained from the Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD, USA. The controls included four agematched subjects without significant or confounding neuropathological findings at autopsy (non-neurological controls). In addition, nine disease controls were used for selected experiments. These included two patients with multiple sclerosis (obtained from The Netherlands Brain Bank, Amsterdam, The Netherlands), one with glioblastoma multiforme (WHO grade IV) and six subjects with different genetic or acquired white matter disorders (adult-onset vascular leukoencephalopathy, diffuse white matter injury due to perinatal hypoxiaischaemia, juvenile-onset Alexander disease, classic Pelizaeus-Merzbacher disease, late infantile-onset metachromatic leukodystrophy and infantile-onset Krabbe disease). Table 1 summarizes the clinical information and destination of the tissue samples. Brain specimens were selected from relatively preserved white matter in the frontal lobe immediately adjacent to cavitary areas and from the cerebellar hemispheres lateral to the nucleus dentatus. Corresponding areas were selected from neurological and non-neurological controls. The tissue was snap frozen and conserved at −80°C. In addition, tissue from Patients 2 and 3 was formalin fixed and paraffin embedded.
The study was approved by the institutional review board, and informed consent was obtained in all cases from patients or parents. (10 ng/ml; Molecular Probes) and photographed using a Leica DM6000B microscope (Leica Microsystems). Immunopositivity on paraffin-embedded material was detected with 3,3′-diaminobenzidine as chromogen.
Immunohistochemical staining
RNA isolation, reverse transcription and real-time quantitative polymerase chain reaction
RNA was extracted from frozen tissue with TRIzol (Invitrogen) and purified using RNeasy® (Qiagen) according to manufacturers' specifications. Subsequent reverse transcription to complementary DNA was performed with SuperScript® III reverse transcriptase (Invitrogen) and quantitative PCR by using a LightCycler 480 II (Roche). Transcript-specific primers were generated with Primer Express software (Applied Biosystems) and designed to overlap exon-exon boundaries to prevent genomic DNA amplification (Table 2 ). The PCR reaction was carried out on a 10-µl volume containing SYBR® green PCR mix, 3.0 µM primers and 0.03 µg of complementary DNA. The relative abundance of transcript expression was calculated using the cycle of threshold value and normalized to the endogenous controls cyclophilin B (CypB) and ribosomal protein, large, P0 (RPLP0). 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis and western blotting
Cell lysates of white matter were obtained as previously described (van der Voorn et al., 2005) . In brief, ~1 mg of material was homogenized in NP40 lysis buffer containing a protease inhibitor cocktail (Roche) with 1 mM dithiothreitol. The supernatants were run on 4-12% sodium dodecyl sulphate-polyacrylamide precast gels (Invitrogen) and transferred onto polyvinylidene difluoride membranes (Immobilon-P; Millipore). The blots were incubated with antibodies against CD44, HAS2, HYAL2 and glyceraldehyde-3-phosphate dehydrogenase as loading control. Proteins were visualized using alkaline phosphatase-coupled secondary antibodies and ECF western blot detection reagent (Amersham).
Size exclusion chromatography
Tissue samples were homogenized and digested with 6 units of pronase E (Sigma) in pronase buffer (50 mM sodium phosphate, 150 mM NaCl, 2% SDS, 50 mM EDTA) for 45 min at 37°C, followed by DNase (Roche; 80 µg/ml) treatment for 15 min at 37°C. All enzymatic activity was stopped by heat inactivation (15 min, 80°C). Samples were centrifuged (3000g, 15 min), and half of the supernatant was used for hyaluronidase digestion (Streptomyces hyaluronlyticus; Merck). Hydrolysis (100 units/ml) was carried out at pH 7 for 50 h at 37°C in pronase buffer containing a protease inhibitor cocktail. With the exception of the hyaluronidase treatment, the non-hydrolyzed samples underwent the same procedures. All samples were then heat inactivated, cooled on ice and incubated with biotinylated HABP (1 µg/ml) overnight at 4°C. The next day, the samples were incubated with anti-streptavidin Alexa Fluor® 488 (1:1000), and a 50-µl volume was used for size exclusion chromatography. Separation and analysis of hyaluronan was performed using fast protein liquid chromatography. The high-performance liquid chromatography system consisted of an Alliance 2695 pump, model 486 absorbance detector and model 2475 fluorescence detector from Waters. Gel chromatography was carried out using a Superose 6 HR 10/30 column (Pharmacia). The column was kept at a constant temperature of 25°C in a water bath. The sample compartment of the auto-sampler was cooled at 7°C, and injected samples were eluted with phosphate buffer saline (pH 7.4) at a flow rate of 0.5 ml/min. Two detectors in series were used to monitor the column effluent: the first to detect UV at 280 nm and the second to measure fluorescence with excitation at 496 nm and emission at 519 nm. The total run time was 70 min.
Quantification and statistical analysis
The total number of labelled and unlabelled cells was counted in at least 10 standardized fields using a ×10 objective lens. For each stained section, immunopositive cells were counted individually and expressed as a percentage of the total number of DAPI + cells to avoid bias due to a different cell density. The results of these counts were compared using an unpaired Student's t-test and the Prism4 software (Graph Pad Software).
Results
The white matter of VWM brains is enriched in astrocyte-restricted precursor cells expressing the transmembrane protein CD44
To investigate whether the increased cellular density in the white matter of patients with VWM may be partially accounted for by astrocyte-restricted precursor cells, we examined the expression of CD44 in brain tissue from patients with VWM as well as non-neurological and disease controls. Immunohistochemistry revealed strong CD44 expression in the white matter of patients with VWM. CD44 staining was strongest in areas close to the cavitated tissue. 1C ). Notably, in normal and multiple sclerosis tissue, a diffuse weak CD44 immunoreactivity was also detectable in the extracellular matrix, indicating CD44 expression in the thinner astrocytic processes. Western blot analysis showed that there was some degree of variability in total protein expression among patients with VWM and multiple sclerosis, conceivably reflecting the different degree of tissue rarefaction and cell density, but that overall both expressed more CD44 than the non-neurological controls (data not shown). CD44 expressed in VWM and multiple sclerosis was ~85 kDa, consistent with the standard transmembrane form and in agreement with the cell surface expression shown by immunohistochemistry. Western blotting revealed a slightly lighter band of ~75 kDa in the non-neurological controls. Quantitative PCR demonstrated that in VWM CD44 transcripts were at least two times more abundant than in the nonneurological controls ( fig. 1D ), indicating that the increased CD44 protein expression was related to enhanced transcription at the messenger RNA level. In agreement with previous results (Bugiani et al., 2011) , the net abundance of the GFAP transcript was not increased in VWM. The highest amounts of GFAP messenger RNA were detected in the multiple sclerosis tissue, as expected for tissue full of reactive astrocytes (data not shown).
Hyaluronan accumulates in the severely affected and cavitated white matter of VWM brains
To test whether elevated CD44 expression coincides with hyaluronan accumulation in VWM, we incubated tissue sections with HABP. We found strong extracellular HABP staining in the frontal white matter of patients with VWM, indicating hyaluronan accumulation ( fig. 2A,B) . HABP staining was strongest in areas enriched in CD44 + astrocyte-restricted precursor cells adjacent to cavitated tissue.
Abundant HABP labelling was also found in multiple sclerosis ( fig. 2C,D ), although to a lesser degree than in VWM, in an elderly subject with vascular white matter changes and in an infant with diffuse white matter injury due to perinatal hypoxiaischaemia (supplementary fig. 1A ,B). The white matter of non-neurological controls , only a few CD44+ astrocytic processes are seen surrounding blood vessels. Note that in multiple sclerosis tissue (B) and non-neurological control (C), a weak fibrous immunopositivity is present between immunopositive cells, suggesting CD44 expression also at the thinner astrocytic processes. In all pictures, nuclei are stained in blue (DAPI). A, B and C: x200 magnification, insets: x400. (D) CD44 messenger RNA expression in VWM frontal white matter is significantly higher than in the white matter of non-neurological controls, but not significantly different from CD44 expression in multiple sclerosis (MS) (*P<0.05 by t-test). CD44 expression was determined by quantitative PCR and presented as relative expression compared with cyclophilin B and RPLP0.
1C-F) showed only minimal HABP immunopositivity. Interestingly, in VWM, HABP immunoreactivity was also detected in the cytoplasm of numerous CD44 + astrocyte-restricted precursor cells ( Fig. 2A and B fig. 1 ). Intracellular localization of hyaluronan has been correlated with cell proliferation in extraneuronal cultures (Evanko & Wight, 1999) . To confirm that intracellular hyaluronan localization is also associated with fast proliferation of brain glial cells, we investigated HABP expression in tissue sections from a patient with glioblastoma multiforme and obtained the same results ( fig. 2F ).
We then determined the amount and the size of hyaluronan in the white matter of two patients with VWM and one non-neurological control by means of size exclusion chromatography. Because of limited tissue availability, the patients with multiple sclerosis were not included among the controls. In both patients with VWM, size exclusion chromatography showed a significant increase in Alexa
Fluor® 488-labelled HABP-bound hyaluronan ( fig. 3 ). Retention time of this hyaluronan species was compatible with a molecular weight of at least 1×10 6 Da, as determined by comparison with different high molecular weight internal controls (data not shown). The specificity of the peak was confirmed by pretreatment with Streptomyces hyaluronidase, an enzyme degrading high molecular weight hyaluronan (data not shown). The total amounts of lower-molecular-weight hyaluronan species were not changed.
Hyaluronan synthase 2 and hyaluronidase 2 expression is increased in the white matter of VWM brains
To determine whether hyaluronan accumulation in VWM may be due to increased synthesis or reduced degradation, we incubated tissue samples with antibodies against HAS2 and HYAL2. These enzymes synthesize and degrade the high molecular weight species of hyaluronan, respectively (Brinck & Heldin, 1999; Sherman et al., 2002) . Immunohistochemical staining of VWM white matter showed HAS2 immunoreactivity in virtually all CD44 + astrocyte-restricted precursor cells ( fig. 4A,B) . HAS2 + /CD44 + cells were enriched in areas close to the cavitated tissue.
In addition, HAS2 labelling identified numerous other cells that co-expressed NG2 or PDGFRα with HAS2 and were CD44 − . These cells had small round nuclei and multiple short processes, consistent with oligodendrocyte progenitor cells in the white matter ( fig. 4C ). The same oligodendrocyte progenitor cell population was immunoreactive for HYAL2 ( fig. 4D) . No detectable HYAL2 labelling was detected fig. 4E ).
The white matter of non-neurological controls showed virtually no HAS2 or HYAL2 immunopositivity ( fig. 4I,J) .
Increased expression of HAS2 and HYAL2 was confirmed in VWM white matter lysates by western blot analysis ( fig. 4K ). Total protein expression among patients with VWM was to some degree variable, but these expressed higher amounts of both enzymes compared with non-neurological and disease controls. HAS2 has a molecular weight of ~63 kDa (www.uniprot.org/uniprot/Q92819). A smaller band was also observed in the patients' tissue samples, which most likely represents a degradation product of HAS2 occurring in post-mortem material. Apart from VWM, a faint band was visible only in the sample obtained from the 4-month-old nonneurological control, consistent with a higher hyaluronan turnover in the extracellular matrix during early postnatal life (Singh & Bachhawat, 1968) . No significant changes in the expression of HAS2 and HYAL2 were detected at the messenger RNA level (data not shown).
CD44 expression and hyaluronan accumulation are less pronounced in the cerebellar than in the frontal white matter of VWM brains
To explore whether CD44 overexpression and hyaluronan accumulation correlate with the severity of white matter abnormalities in VWM, we extended our study to the cerebellum. The cerebellar white matter is often hypomyelinated in VWM, but seldom undergoes massive tissue cavitation even late in the course of the disease (supplementary fig. 2A ).
Immunohistochemistry of cerebellar tissue sections showed numerous GFAP + /CD44 + astrocytes ( fig. 5A and B). CD44 immunoreactivity was restricted to the cell membrane. However, compared with the severely affected and cavitated frontal white matter, only a few CD44 + cells with the bipolar morphology of astrocyte-restricted precursor cells were seen ( fig. 5A and supplementary fig. 2D ). Most CD44 + cells had multiple processes, consistent with the morphology of more mature astrocytes ( fig. 5B and supplementary fig. 2B ,C). To ascertain the maturation status of these cells, tissue sections were incubated with antibodies against nestin and S100β, which are expressed in immature and fully differentiated cells, respectively (Eliasson et al., 1999; Raponi et al., 2007; Middeldorp et al., 2010) . As already reported for the frontal white matter (Bugiani et al., 2011) , the astrocytes in the patients' cerebella were nestin + and S100β − (supplementary fig.   2E ,F). Expression of CD44 was confirmed by western blotting, and CD44 messenger RNA transcripts were two times more abundant in the cerebellum of patients with VWM than in controls (data not shown).
Immunostaining for HABP detected a diffuse positivity in the extracellular space of the patients' cerebella ( fig. 5C,D) , which, however, was less intense than in the cavitated frontal white matter. Moreover, only a subset of GFAP + or CD44
+ astrocytes displayed an intracellular HABP immunopositivity (fig 5C,D and inset).
Western blot analysis confirmed increased expression of HYAL2 in the VWM cerebellar white matter. However, HAS2 protein levels were comparable with those in the non-neurological control ( fig. 5E ). No significant changes in HAS2 or HYAL2 expression were detected at the messenger RNA level (data not shown). We determined the amounts and size of the hyaluronan species accumulating in the cerebellum of two patients with VWM by means of size exclusion chromatography. The results were compared with the same patients' frontal white matter and one age-matched non-neurological control. A significant increase in high molecular weight hyaluronan was detected in the cerebellum of both patients with VWM compared with the non-neurological control. However, as expected from the HABP staining, hyaluronan amounts in the cerebellum were much lower than in the cavitated frontal tissue. In the non-neurological control, hyaluronan amounts in the cerebellum were comparable with those in the frontal white matter ( fig. 5F ).
Oligodendrocyte progenitor cell maturation is inhibited in the frontal but not the cerebellar white matter of VWM brains
To investigate whether hyaluronan accumulation may be a causal determinant of the lack of myelin in VWM, we compared hyaluronan amounts, oligodendrocyte progenitor cell numbers and immunoreactivity for the mature myelin protein, proteolipid protein (PLP), in the frontal and cerebellar white matter of two patients with VWM. Myelin is virtually absent in the more severely affected cerebrum of patients with VWM and variably reduced in relatively spared regions, including the cerebellum (van der Knaap et al., 2006; Bugiani et al., 2010) . Consistent with this, markedly reduced PLP immunoreactivity was detectable in the patients' frontal white matter ( fig. 6A,B A recent study in multiple sclerosis reported that hyaluronan blocks oligodendrocyte progenitor cell maturation and remyelination through stimulation of the Toll-like receptor 2 (TLR2) signalling pathway (Sloane et al., 2010) . To assess whether the same pathway is involved in hyaluronan-mediated inhibition of oligodendrocyte progenitor cell maturation in VWM, we checked the amounts of TLR2 messenger RNAs in patients with VWM, the non-neurological controls and 
Discussion
Expansion of the astrocyte-restricted precursor cell population and accumulation of high molecular weight hyaluronan in VWM
VWM is a leukodystrophy with unique neuropathological features. Typical is the rarefaction of the cerebral white matter, which occurs without reactive glial scarring and results in often massive tissue cavitation (van der Knaap et al., 2006; Bugiani et al., 2010) . We have previously shown that in VWM the maturation of astrocytes is halted, and only few mature astrocytes are observed (Bugiani et al., 2011) . In the present study, we found that the VWM white matter is enriched in astrocyterestricted precursor cells expressing the transmembrane hyaluronan receptor CD44 and accumulates hyaluronan.
Although not required for hyaluronan synthesis, CD44 regulates cellular responses to hyaluronan and the assembly of hyaluronan-rich extracellular matrices (Sherman et al., 2002) . Western blotting of VWM patient and control white matter lysates identified a band with a molecular weight between 75 and85 kDa, compatible with the standard transmembrane form of CD44. This form predominates in the normal and injured white matter, and has a much higher hyaluronan-binding efficiency than other splice variants of CD44 (Kaaijk et al., 1997; Sherman et al., 2002) . The slightly different molecular weight seen in VWM of white matter cell lysates shows inhomogeneous, but overall increased, HAS2 and HYAL2 protein expression in the VWM white matter compared with multiple sclerosis (MS) and non-neurological control tissue. Note that for the controls, low HYAL2 protein amounts are detectable only in the sample obtained from a 4-month-old infant (Control 1, Lane 1). In the top blot, the arrowhead points to a molecular weight of 63 kDa. The bottom blot shows the loading control glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 37 kDa). In the western blot, lane numbers identify subjects according to shows that HAS2 protein amounts are increased in the frontal white matter of patients with ) VWM, but not in the cerebellum (cereb). The arrowhead points to a molecular weight of 63 kDa. HYAL2
and multiple sclerosis tissue compared with control white matter suggests some degree of diversity in post-translational modification of CD44 after injury (Cichy & Pure, 2003; Thorne et al., 2004) . Expansion of the CD44 + astrocytic population has been described in different pathological conditions, including stroke, chronic multiple sclerosis lesions, chronic white matter injury of premature infants and vascular injury to the white matter in older adults (Sherman et al., 2002; Back et al., 2005 Back et al., , 2011 Al'Qteishat et al., 2006; Buser et al., 2012) . In these settings, CD44
+ cells have been regarded as reactive astrocytes arising in the context of reactive gliosis. In VWM, by contrast, CD44 expression is found in astrocyte-restricted precursor cells, whereas reactive gliosis is barely observed.We found that, concurrent with enrichment in CD44 + astrocyte-restricted precursor cells, the VWM white matter accumulates vast amounts of high molecular weight hyaluronan. In the CNS white matter, hyaluronan is produced predominantly by astrocytes and to a lesser extent by oligodendrocytes, NG2 + oligodendrocyte progenitor cells and microglia (Marret et al., 1994; Butt et al., 2005; Sherman & Back, 2008) .
Hyaluronan species of different size are generated by different hyaluronan synthases (HAS1, HAS2 and HAS3) and further modified by hyaluronidases (HYAL1, HYAL2, HYAL3 and SPAM1) (Sherman et al., 2002; Sherman & Back, 2008) . Under physiological conditions, hyaluronan exists as a high molecular weight polymer (≥1×10 6 Da). However, after injury, high molecular weight hyaluronan is rapidly degraded into smaller units (1×10 4 to 1×10 3 Da) and, as reactive gliosis proceeds, new high molecular weight hyaluronan is overproduced around the glial scar (Struve et al., 2005) . How hyaluronan synthases and hyaluronidases are regulated after injury is not known. In VWM, hyaluronan accumulation is associated with increased protein levels of HAS2, generating high molecular weight hyaluronan species, and with strong HAS2 immunoreactivity in CD44 + astrocyte-restricted precursor cells, immature astrocytes and NG2 + Figure 5 (cont.). protein levels are also increased in VWM white matter, although inhomogeneously.
The bottom blot shows the loading control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In the western blot, lane numbers identify subjects according to Table 1 . (F) Size exclusion chromatography of white matter homogenates shows that hyaluronan accumulates to a greater extent in the frontal than in the cerebellar white matter of two patients with VWM (Patients 3 and 2, black and red trace, respectively; the solid line indicates the frontal and the dashed line the cerebellar samples). In an age-matched non-neurological control (Control 3, green traces) comparable amounts of hyaluronan are found in the frontal and cerebellar samples. Time retention of the accumulated hyaluronan is indicative of a high molecular weight species of at least 1x10 6 Da (15-min retention time). We found that, in the VWM white matter, numerous CD44-overexpressing astrocyte-restricted precursor cells show cytoplasmic expression of hyaluronan. Scattered CD44 + reactive astrocytes with intracellular HABP immunoreactivity were also observed in multiple sclerosis, the elderly individual and the infant with acquired white matter injury. We do not know the reasons and functional consequences of this finding. CD44 mediates uptake of hyaluronan, and hyaluronan internalization is dependent on the degree of CD44 expression (Thorne et al., 2004) . Intracellular localization of hyaluronan is associated with cell proliferation in extraneuronal cultures (Evanko & Wight, 1999) and in glioblastoma multiforme brain tissue (present study). In VWM, increased proliferation of cells in the astrocytic lineage co-exists with a defect in their maturation in vivo and in vitro (Bugiani et al., 2011) . Taken together, these findings suggest that intracellular accumulation of hyaluronan in VWM astrocyte-restricted precursor cells may be related to CD44 overexpression and contribute to increased cell proliferation.
Hyaluronan accumulation parallels the degree of tissue loss in the VWM white matter
We found that high molecular weight hyaluronan accumulates especially in white matter areas enriched in astrocyte-restricted precursor cells and undergoing tissue cavitation. This finding suggests that in VWM, high molecular weight hyaluronan influences astrocyte maturation and the degree of glial scarring.
In vitro and in vivo studies have documented that different hyaluronan forms act on astrocytic behaviour during reactive gliosis and in the scar environment.
Hyaluronan maintains astrocytes in a state of quiescence after injury, and high molecular weight species inhibit astrocyte proliferation and glial scarring (Hou et al., 2005; Struve et al., 2005; Bourguignon et al., 2007; Lin et al., 2009; Khaing et al., 2011) . Conversely, hyaluronan degradation promotes astrocyte proliferation (Struve et al., 2005) . In VWM, high molecular weight hyaluronan accumulates in the affected white matter, but the amounts of low molecular weight hyaluronan are not changed. This finding indicates that degradation of larger hyaluronan molecules to smaller species is limited, which is in agreement with the meagre reactive gliosis typically seen in VWM (Bugiani et al., 2010) . Comparison of the variably affected frontal and cerebellar white matter also shows that accumulation of high molecular weight hyaluronan is a feature of VWM, and that its overabundance positively correlates with the degree of tissue loss and enrichment in astrocyte-restricted precursor cells. Overall, these observations support a role for high molecular weight hyaluronan in inhibiting reactive gliosis and glial scarring through halting the maturation of VWM astrocytes.
Hyaluronan accumulation coincides with inhibited oligodendrocyte progenitor cell maturation in the VWM white matter
We found that in the VWM white matter hyaluronan accumulates in areas where the lack of myelin co-exists with increased oligodendrocyte progenitor cell numbers. Comparison of variably affected regions showed that oligodendrocyte progenitor cell numbers are higher, and amounts of PLP + myelin scantier, in the frontal white matter where hyaluronan accumulates to a larger degree. Conversely, in the cerebellum, hyaluronan levels are only slightly increased, and oligodendrocyte progenitor cell numbers and myelination are less affected. We have previously shown that the VWM oligodendrocyte progenitor cells regenerate but survive in a state of arrested maturation, so that oligodendrocyte progenitor cell numbers are disproportionate to the numbers of mature myelinating oligodendrocytes (Bugiani et al., 2011) . The present findings are compatible with the block of oligodendrocyte progenitor cell maturation in VWM being hyaluronan mediated.
Hyaluronan has major effects on oligodendrocyte progenitor cell behaviour and reactive changes in response to injury (Marret et al., 1994) . In chronic demyelinated lesions from patients with multiple sclerosis and in mice with experimental autoimmune encephalomyelitis, hyaluronan accumulates in regions enriched in CD44 + astrocytes where oligodendrocyte progenitor cells are held in an immature state and no remyelination occurs (Back et al., 2005; Struve et al., 2005) .
A proposed mechanism for hyaluronan-mediated remyelination failure in multiple sclerosis implies degradation of high molecular weight hyaluronan into smaller fragments that block oligodendrocyte progenitor cell maturation through stimulation of TLR2, a receptor for hyaluronan in the context of innate immune cell activation (Sloane et al., 2010) . TLR2 overexpression in our multiple sclerosis control tissue is in agreement with this hypothesis. In VWM, by contrast, no inflammation is present, and the levels of low molecular weight hyaluronan and expression of TLR2 are not increased. These data suggest that in non-inflammatory conditions, hyaluronan-mediated inhibition of oligodendrocyte progenitor cell maturation takes place via activation of pathways other than TLR2 signalling.
Several studies have reported an inflammation-independent negative effect of hyaluronan on myelin formation and maintenance. Notably, as VWM, these conditions feature an abnormal expansion of the oligodendrocyte progenitor cell pool. In mice, transgenic overexpression of CD44 under the control of a myelinspecific promoter leads to accumulation of high molecular weight hyaluronan and, depending on the expression level, to dysmyelination or demyelination in the absence of obvious remyelination (Tuohy et al., 2004; Back et al., 2005) . In premature infants with diffuse white matter injury, failure of developmental myelination is associated with hyaluronan build-up and arrested oligodendrocyte progenitor cell maturation (Buser et al., 2012) . In individuals with age-related cognitive decline, vascular injury to the white matter is characterized by an abnormal reactive response of oligodendrocyte lineage cells in hyaluronan-rich areas (Back et al., 2011) . Interestingly, we observed negligible hyaluronan accumulation in genetic white matter disorders featuring oligodendrocytic loss (Alexander disease, Pelizaeus-Merzbacher disease, metachromatic leukodystrophy and Krabbe disease, present study) (Woodward, 2008; Faust et al., 2010; Tian et al., 2010) . Overall, these data indicate that, even when reactive expansion of the oligodendrocyte progenitor cell pool occurs, hyaluronan-related inhibition of oligodendrocyte progenitor cell maturation is a general mechanism limiting developmental myelination and remyelination in the context of chronic white matter injury.
In conclusion, we propose that the massive presence of CD44 + astrocyte-restricted precursor cells in the white matter of VWM brains results in the assembly of a high molecular weight hyaluronan-rich matrix. The altered hyaluronan matrix impacts many of the cellular processes important in gliosis, including astrocyte maturation, intermediate filament composition and hyperplasia. In parallel, overabundance of hyaluronan arrests oligodendrocyte progenitor cell maturation at a pre-myelinating state, reducing the numbers of mature oligodendrocytes available for myelin deposition. By inhibiting maturation and proper function of both astrocytes and oligodendrocytes, the high molecular weight hyaluronan-rich matrix can be a major determinant of VWM white matter pathology, and therefore becomes a putative target to alter a microenvironment that is primarily abnormal and non-permissive for repair.
